The British Journal of Clinical Pharmacology

Volume 22
1986

Published for
The British Pharmacological Society by
Blackwell Scientific Publications

© 1986 Blackwell Scientific Publications
Osney Mead, Oxford OX2 0EL
8 John Street, London WC1N 2ES
23 Ainslie Place, Edinburgh EH3 6AJ
52 Beacon Street, Boston, Mass. 02108, USA
667 Lytton Avenue, Palo Alto, Calif. 94301, USA
107 Barry Street, Carlton, Victoria 3053, Australia

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Scientific Publications for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $02.00 per copy is paid directly to CCC, 27 Congress Street, Salem, MA 01970, USA. 0306-5251/86 $02.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by Oxprint Ltd, Oxford
Printed in Great Britain
at the University Press, Cambridge

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

Contents

Number 1, July 1986

Papers

1 Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201–403 by an integrated pharmacokinetic–pharmacodynamic model: *J. Grevel, J. Brownell, J. L. Steimer, R. C. Gaillard & J. Rosenthaler*

15 Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina: *D. P. Nicholls, K. Moles, D. N. S. Gleadhill, K. Booth, J. Rowan & P. Morton*

21 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily: *J. K. Faulkner, D. McGibney, L. F. Chasseaud, J. L. Perry & I. W. Taylor*

27 *In vivo* cation transport during short-term and long-term digoxin therapy: *N. A. Boon, S. E. Pugh, K. F. Hallis, J. K. Aronson & D. G. Grahame-Smith*

31 Cardiovascular toxicity and distribution kinetics of intravenous chloroquine: *S. Looareesuwan, N. J. White, P. Chanthavanich, G. Edwards, D. D. Nicholl, C. Bunch & D. A. Warrell*

37 Investigation of patients with abnormal response to warfarin, *D. P. Bentley, G. Backhouse, A. Hutchings, R. L. Haddon, B. Spragg & P. A. Routledge*

43 Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide—drug interaction or summation of similar effects: *T. Richardson, J. Foster & G. E. Mawer*

49 The influence of enzyme induction on polymorphic sparteine oxidation: *M. Eichelbaum, S. Mineshita, E. E. Ohnhaus & C. Zekorn*

55 Renal failure does not impair the metabolism of morphine: *D. F. Woolner, D. Winter, T. J. Frendin, E. J. Begg, K. L. Lynn & G. J. Wright*

61 Comparative disposition of codeine and pholcodine in man after single oral doses: *J. W. A. Findlay, A. S. E. Fowle, R. F. Butz, E. C. Jones, B. C. Weatherley, R. M. Welch & J. Posner*

73 Acute treatment with desipramine stimulates melatonin and 6-sulphatoxy melatonin production in man: *C. Franey, M. Aldhous, S. Burton, S. Checkley & J. Arendt*

81 The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects: *M. Bruce, N. Scott, M. Lader & V. Marks*

Short reports

89 Inhibitory effects of neuroleptics on debrisoquine oxidation in man: *E. K. G. Syvälahti, R. Lindberg, J. Kallio & M. De Vocht*

93 *In vitro* activity of chloroquine, the two enantiomers of chloroquine, desethyl-chloroquine and pyronaridine against *Plasmodium* falciparum: *S. Fui, A. Björkman, B. Wåhlin, D. Ofori-Adjei, Ö. Ericsson & F. Sjöqvist*

97 Effects of paroxetine on human sleep: *I. Oswald & K. Adam*

100 Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs: *R. N. Ratnaike, G. J. Schapel, G. Purdie, R. H. C. Rischbieth & S. Hoffmann*

104 Exercise-induced hand tremor: a possible test for β_2-adrenoceptor selectivity in man? *B. Abila, J. F. Wilson, R. W. Marshall & A. Richens*

108 Altered pharmacokinetics of oral flecainide by cimetidine: *T. B. Tjandra-Maga, A. van Hecken, P. van Melle, R. Verbesselt & P. J. de Schepper*

111 Paracetamol absorption from a feeding jejunostomy: *E. B. Nelson, D. R. Abernethy, D. J. Greenblatt & B. Ameer*

114 Comparison of single doses of ketanserin and placebo in chronic stable angina: *H. A. Cameron, C. M. Cameron & L. E. Ramsay*

Letters to the Editors

117 Nitrendipine enhances the effect of adrenaline on serum potassium in normal man: *A. Mimran & J. Ribstein*

118 Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost *in vitro*: *U. Alt, P. J. Leigh, A. J. Wilkins, P. K. Morris & J. MacDermot*

119 Effects of trazodone and nadolol upon human sperm motility: *S. L. Cassidy & R. M. Pearson*

121 Metabolite residence time: influence of the first-pass effect: *M. Weiss*

Number 2, August 1986

Papers

125 The effect of cigarette smoking on 7-ethoxyresorufin *O*-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies: *O. Pelkonen, M. Pasanen, H. Kuha, B. Gachalyi, M. Kairaluoma, E. A. Sotaniemi, S. S. Park, F. K. Friedman & H. V. Gelboin*

135 Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid: *J. O. Miners, N. Grgurinovich, A. G. Whitehead, R. A. Robson & D. J. Birkett*

143 Dose determinants of rebound insomnia: *T. A. Roehrs, F. J. Zorick, R. M. Wittig & T. Roth*

149 A comparison of the ventilatory, cardiovascular

and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide formation in normal subjects: *A. M. Morice, P. Schofield, E. E. Keal & P. S. Sever*
155 Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin: *W. Kirch, J. Stenzel, P. Dylewicz, H. J. Hutt, S. R. Santos & E. E. Ohnhaus*
161 Drug-specific antibodies in patients receiving captopril: *J. W. Coleman, J. H. K. Yeung, D. H. Roberts, A. M. Breckenridge & B. K. Park*
167 The pharmacodynamics and dose–response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension: *A. A. Ajayi, H. L. Elliott & J. L. Reid*
177 Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man: *A. Lelo, D. J. Birkett, R. A. Robson & J. O. Miners*

Short reports
183 Quantitative assessment of caffeine partial clearances in man: *A. Lelo, J. O. Miners, R. A. Robson & D. J. Birkett*
187 Effect of oral verapamil on glibenclamide stimulated insulin secretion: *C. G. Semple, C. Omile, K. D. Buchanan, G. H. Beastall & K. R. Paterson*
191 The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy: *S. Jawad, J. Oxley, W. C. Yuen & A. Richens*
194 Sparteine oxidation is practically abolished in quinidine-treated patients: *R. Brinn, K. Brøsen, L. F. Gram, T. Haghfelt & S. V. Otton*

Letters to the Editors
199 Quinidine: potent inhibition of sparteine and debrisoquine oxidation *in vivo*: *T. Inaba, R. E. Tyndale & W. A. Mahon*
200 Effects of verapamil and nisoldipine on human platelets: *in vivo* and *in vitro* studies: *J. Y. Jeremy, M. A. Barradas, D. P. Mikhailidis & P. Dandona*

Proceedings
203 Proceedings of the British Pharmacological Society (University of Bath, 9–11 April 1986)

Number 3, September 1986

249 **Editor's note**

Review article
251 States of anxiety and their induction by drugs: *M. Lader & M. Bruce*

Papers
263 Ethyoxyresorufin *O*-deethylation by human liver microsomes: *F. M. Williams, E. Mutch, K. W. Woodhouse, D. Lambert & M. D. Rawlins*
269 Valpromide inhibits human epoxide hydrolase: *G. M. Pacifici, M. Franchi, C. Bencini & A. Rane*
275 The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [^{3}H]-ouabain binding to human lymphocytes after incubation for 3 days: *W. G. Rapeport, J. K. Aronson, D. G. Grahame-Smith & C. Harper*
281 Relationship between α_1-acid glycoprotein and distribution of disopyramide and mono-*N*-dealkyldisopyramide in whole blood: *J. E. Bredesen & P. Kierulf*
287 Acute haemodynamic effects of pinacidil in man: *D. P. Nicholls, J. G. Murtagh, M. E. Scott, P. Morton & R. G. Shanks*
293 Pharmacodynamic profile of bisoprolol, a new β_1-selective adrenoceptor antagonist: *G. Leopold, W. Ungethüm, J. Pabst, Z. Simane, K. U. Bühring & H. Wiemann*
301 Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers: *F. M. Williams, J. E. Leeser & M. D. Rawlins*
309 Flecainide; single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man: *T. B. Tjandra-Maga, R. Verbesselt, A. Van Hecken, A. Mullie & P. J. de Schepper*
317 Partial metabolic clearances as determinants of the oral bioavailability of propranolol: *T. Walle, U. K. Walle, L. S. Olanoff & E. C. Conradi*
325 The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non insulin dependent diabetics: *D. R. Owens, J. Vora, T. Morris, S. Luzio, R. E. J. Ryder, J. Atiea & T. M. Hayes*
331 Pharmacokinetics of intravenously administered haem arginate: *O. Tokola, R. Tenhunen, L. Volin & P. Mustajoki*
337 Acute and chronic pharmacokinetics of assymetrical doses of slow release choline theophyllinate in asthma: *S. G. Hibberd, C. Alveyn, E. J. Coombes & S. T. Holgate*

Short reports
343 A simple method for determining acetylator phenotype using isoniazid: *A. Hutchings & P. A. Routledge*
346 Effects of cimetidine and ranitidine on the pharmacokinetics of quinine: *S. Wanwimolruk, M. Sunbhanich, M. Pongmarutai & P. Patamasucon*
351 Theophylline pharmacokinetics after intravenous infusion with ethylenediamine or sodium glycinate: *J. Caldwell, A. H. Staib, I. A. Cotgreave & M. Siebert-Weigel*
356 Protein binding of chloroquine enantiomers and desethylchloroquine: *D. Ofori-Adjei, Ö. Ericsson, B. Lindström & F. Sjöqvist*
359 Paracetamol metabolism in pregnancy: *J. O. Miners, R. A. Robson & D. J. Birkett*

363 Is biliary excretion of paracetamol significant in man?: *K. S. A. Jayasinghe, C. J. C. Roberts & A. E. Read*
367 Excretion of trazodone in breast milk: *R. K. Verbeeck, S. G. Ross & E. A. McKenna*

Letters to the Editors
371 Loperamide and oro-caecal transit delay: *G. Basilisco, G. Camboni, A. Bozzani & P. A. Bianchi*
372 The influence of loperamide on oro-caecal transit time: *M. Van Wyk, D. Sommers & A. G. W. Steyn*

Number 4, October 1986

Papers
373 The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration: *M. G. Neale, K. Brown, R. W. Hodder & R. M. Auty*
383 Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma: *P. E. Williams, Y. A. Alwazir, P. A. Routledge & I. A. Campbell*
389 Comparison of levocabastine, a new selective H_1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen: *M. Kolly & A. Pécoud*
395 The antisecretory effects of zaltidine, a novel long-acting H_2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer: *G. Laferla, N. Buchanan, J. Hearns, G. P. Crean, K. E. L. McColl & A. T. Clucas*
401 The effect of glucose on acetylation status: *D. Suhardjono, J. Boutagy & G. M. Shenfield*
409 Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside: *R. H. A. Becker, A. D. Struthers & M. J. Brown*
415 Sparteine oxidation polymorphism in Greenlanders living in Denmark: *K. Brøsen*
421 Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration: *G. Roncari, W. H. Ziegler & T. W. Guentert*
429 The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations: *R. J. Hardie, S. L. Malcolm, A. J. Lees, G. M. Stern & J. G. Allen*
437 Comparison of the analgesic effect of a corticosteroid and paracetamol in patients with pain after oral surgery: *O. A. Olstad & P. Skjelbred*
443 Dose-dependent inhibition of phosphoinositide metabolism in human platelets by aspirin *in vitro* and *in vivo*: *P. P. Godfrey, F. Bochner & D. G. Grahame-Smith*
449 Clinical and rheological effects of nifedipine in Raynaud's phenomenon: *D. G. Waller, V. F. Challenor, D. A. Francis & O. S. Roath*
455 Antipyrine clearance and metabolism in patients with psoriasis: *K. Kubota, T. Ishizaki, K. Chiba, A. Takagi, A. Nakagawa & K. Nakamura*
463 The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction: *M. B. Maltz, D. W. Davies, C. P. Lau, J. E. Creamer, S. O. Banim & A. J. Camm*
469 Comparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with impaired renal function: *J. van der Meulen, E. Reijn, G. A. K. Heidendal, P. L. Oe & A. J. M. Donker*

Short reports
475 Urinary metabolites of caffeine in pregnant women: *N. R. Scott, J. Chakraborty & V. Marks*
479 Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man: *P. Chiodera, R. Volpi, R. Delsignore, C. Marchesi, G. Salati, L. Camellini, G. Rossi & V. Coiro*
483 Effect of calcium antagonists on histamine release from human basophil leukocytes: *A. Miadonna, A. Tedeschi, E. Leggieri, M. Lorini, M. Froldi & C. Zanussi*
487 The effect of inhaled 5-hydroxytryptamine (5-HT, serotonin) on airway calibre in man: *M. J. Cushley, L. H. Wee & S. T. Holgate*
491 The pharmacokinetics of dapsone after oral administration to healthy volunteers: *F. A. J. M. Pieters & J. Zuidema*

Letters to the Editors
495 Comparative effects of famotidine and cimetidine on 7-ethoxycoumarin *O*-deethylase activity in human livers: *Y. Imai, M. Inada, S. Tamura, S. Kawata, Y. Minami & S. Tarui*
496 Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug: *C. de Paolis, R. Farina, E. Pianezzola, G. Valzelli, F. Celotti & A. E. Pontiroli*

Number 5, November 1986

Review article

499 The plasma protein binding of basic drugs: *P. A. Routledge*

Papers

507 Effects of μ-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man: *C. M. Bradley & A. N. Nicholson*

513 Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?: *U. Klotz, G. Ziegler, B. Rosenkranz & G. Mikus*

521 Plasma [^{3}H]-noradrenaline kinetics and blood pressure following regular, moderate ethanol consumption: *L. G. Howes, A. MacGilchrist, C. Hawksby, D. Sumner & J. L. Reid*

527 Pharmacodynamic and pharmacokinetic studies on bufuralol in man: *T. H. Pringle, R. J. Francis, P. B. East & R. G. Shanks*

535 The action of a dopamine (DA_1) receptor agonist, fenoldopam in human vasculature *in vivo* and *in vitro*: *A. Hughes, S. Thom, G. Martin, D. Redman, S. Hasan & P. Sever*

541 Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices: *P. R. Jackson, G. T. Tucker, M. S. Lennard & H. F. Woods*

551 Obesity effects on nitrazepam disposition: *D. R. Abernethy, D. J. Greenblatt, A. Locniskar, H. R. Ochs, J. S. Harmatz & R. I. Shader*

559 Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans: *A. Fadeke Aderounmu, L. A. Salako, B. Lindström, O. Walker & L. Ekman*

565 The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine: *V. Challenor, D. G. Waller, B. S. Gruchy, A. G. Renwick, C. F. George, E. T. McMurdo & J. McEwen*

571 Food induced changes in theophylline absorption from a once-a-day theophylline product: *G. Steffensen & S. Pedersen*

579 Effect of glycopyrrolate and atropine on thermoregulation after exercise: *K. H. Simpson, J. H. Green & F. R. Ellis*

587 Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate: *D. J. Morgan, J. D. Paull, B. H. Richmond, E. Wilson-Evered & S. P. Ziccone*

595 A comparative study of the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients: *J. W. J. Lammers, M. E. T. M. Müller, H. Th. M. Folgering & C. L. A. van Herwaarden*

Short reports

603 The effect of age on theophylline clearance in normal subjects: *W. C. Randolph, J. J. Seaman, B. Dickson, K. E. Peace, W. O. Frank & M. D. Young*

606 The effect of oral verapamil therapy on antipyrine clearance: *D. O. Rumiantsev, V. K. Piotrovskii, O. S. Riabokon, I. D. Slastnikova, E. V. Kokurina & V. I. Metelitsa*

610 Inhibition of antipyrine metabolism by interferon: *S. J. Williams & G. C. Farrell*

613 Salivary concentrations of pirmenol as a possible cause of unpleasant taste: *B. F. Johnson, V. Shekar, T. Woodman & A. T. Canada*

Letters to the Editors

617 Plasma concentrations of theophylline and its metabolites in a theophylline intoxicated child—reevaluation of published K_m-values: *U. Gundert-Remy, B. Krüdewagen & R. Hildebrandt*

619 Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation: *U. Klotz, G. Mikus, C. Zekorn & M. Eichelbaum*

620 Melatonin and cortisol increase after fluvoxamine: *K. Demisch, H. J. Bochnik, T. Nickelsen, P. H. Althoff, K. Schöffling & R. Rieth*

Number 6, December 1986

Review article

623 Platelet α-adrenoceptors—a valid model for brain or vascular adrenoceptors?: *C. A. Hamilton & J. L. Reid*

Papers

627 Topical steroid treatment reduces arachidonic acid and leukotriene B_4 in lesional skin of psoriasis: *E. Wong, R. M. Barr, F. M. Cunningham, K. Mistry, P. M. Woollard, A. I. Mallet & M. W. Greaves*

633 The disposition of intravenous L-tryptophan in healthy subjects and in patients with liver disease: *M. Rössle, R. Herz, K. D. Mullen & D. B. Jones*

639 Population study of triazolam pharmacokinetics: *H. Friedman, D. J. Greenblatt, E. S. Burstein, J. S. Harmatz & R. I. Shader*

643 Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis: *N. A. T. Hamdy, H. J. Kennedy, J. Nicholl & D. R. Triger*

649 Inter-subject and ethnic differences in paracetamol metabolism: *J. A. J. H. Critchley, G. R. Nimmo, C. A. Gregson, N. M. Woolhouse & L. F. Prescott*

659 The relationship between gastric emptying of semisolids and paracetamol absorption: *O. U. Petring, B. Adelhøj, M. Ibsen & H. E. Poulsen*

663 The effectiveness of ranitidine in reducing gastric

acid secretion decreases with continued therapy: *P. J. Prichard, D. B. Jones, N. D. Yeomans, G. W. Mihaly, R. A. Smallwood & W. J. Louis*
669 *In vitro* responsiveness of human asthmatic bronchus to carbachol, histamine, β-adrenoceptor agonists and theophylline: *R. G. Goldie, D. Spina, P. J. Henry, K. M. Lulich & J. W. Paterson*
677 The influence of quinolone derivatives on theophylline clearance: *W. J. A. Wijnands, T. B. Vree & C. L. A. van Herwaarden*
685 Microcalorimetric studies on the effect of adenosine receptor agonists and xanthine derivatives on overall metabolism in human platelets: *L. Edvinsson, J. Ikomi-Kumm & M. Monti*
691 β-adrenoceptor antagonists increase sinus arrhythmia, a vagotonic effect: *S. B. Bittiner & S. E. Smith*
697 A rest and exercise haemodynamic evaluation of a new cardioselective β-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease: *B. Silke, S. P. Verma, M. A. Frais, G. Reynolds & S. H. Taylor*
707 Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction: *B. Silke, M. A. Frais, S. P. Verma, G. W. Reynolds, M. Hafizullah, P. A. Kalra, N. C. Jackson & S. H. Taylor*

Short reports

715 The hypnotic effects of an antihistamine: promethazine: *K. Adam & I. Oswald*
718 No effects on sleep of a histamine H_1-receptor antagonist: temelastine: *K. Adam & I. Oswald*
721 Pharmacokinetic profile of indoprofen in elderly subjects: *B. Lund, C. Egsmose, O. Knudsen & R. B. Andersen*
725 The effects of age on carbamazepine pharmacokinetics and adverse effects: *N. Hockings, A. Pall, J. Moody, A. V. M. Davidson & D. L. W. Davidson*
729 Enantiomers of warfarin and vitamin K_1 metabolism: *I. A. Choonara, B. P. Haynes, S. Cholerton, A. M. Breckenridge & B. K. Park*
733 Excretion of chloroquine, dapsone and pyrimethamine in human milk: *M. D. Edstein, J. R. Veenendaal, K. Newman & R. Hyslop*
736 Peripheral neutrophil inclusions in amiodarone treated patients: *P. C. Adams, P. Sloan, A. R. Morley & D. W. Holt*
739 Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine: *C. J. Speirs, S. Murray, A. R. Boobis, C. E. Seddon & D. S. Davies*
744 The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction: *D. E. Price, A. Mehta, B. K. Park, A. Hay & M. P. Feely*

Letters to the Editors

749 Famotidine and ranitidine control of 24 h intragastric acidity after single bedtime administration: a study using continuous pH monitoring: *V. Varino, G. S. Mela, P. Scalabrini, E. Di Timoteo, M. R. Magnolia, G. Percario & G. Celle*
751 The mechanism of the hypertensive effects of ketanserin: a comparison with metoprolol: *E. Casiglia, R. Gava, A. Semplicini, P. Nicolin & A. C. Pessina*
752 Is there any interaction between digoxin and enalapril?: *Ph. Douste-Blazy, M. Blanc, J. L. Montastruc, D. Conte, J. Cotonat & F. Galinier*

Indexes

755 Author and subject indexes to Volume 22

Supplement 1 to Volume 22, 1986
Clinical pharmacology: the interface between medicine and the pharmaceutical industry

Session 1

3S Aspects of drug research and development: *C. Downie*
5S Basic drug research in universities and industry: *Sir James Black*
9S Drug research and development in the pharmaceutical industry: *B. W. Cromie*
15S Contribution of universities to drug evaluation: *J. McEwan*
19S Attitudes to development of drug therapy in Scandinavia: *F. Sjöqvist & G. Boethius*
27S The pharmaceutical industry and developing countries: *A. M. Breckenridge*

Session 2

31S Problems related to drug development: *C. T. Dollery*
33S Profitability and improved patient care—industry's viewpoint: *E. S. Snell*
41S Profitability and improved patient care—the physician's viewpoint: *P. Turner*
45S The economics of drug development and use: *G. Teeling-Smith*
49S Organisation and problems of drug evaluation in multicentre clinical trials: *O. de S. Pinto*
55S Therapeutic auditing at the national and international level: *B. Westerholm*
61S Is the current training of pharmaceutical industry staff adequate?: *S. L. Dombey*

Session 3

65S Aspects of drug use and safety: *O. L. Wade*
67S Development of drug regulating authorities: *A. Goldberg*

71S Post-marketing surveillance in the UK (1984): *D. H. Lawson*
77S The role of record linkage in post-marketing drug surveillance: *I. K. Crombie*
83S Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries: *J. P. Griffin*
101S The media and their influence on public attitudes to drug development and use: *M. O'Donnell*
103S Symposium summary: *D. G. McDevitt*
105S Personal tribute to Jim Crooks: *O. L. Wade*

Supplement 2 to Volume 22, 1986
Isoxicam—the evolving perspective

107S Editorial note: *C. F. George*
109S Introductory remarks: *P. Brooks*
111S Oxicams: relative safety and anti-injury effects in rats: *M. W. Whitehouse*
117S The effect of isoxicam on neutrophil and monocyte function: *J. G. Martinez, S. I. Murakami & M. A. Scheinberg*
121S Experience with isoxicam and catabolin: *H. Sheppeard & K. G. Couchman*
125S The effect of isoxicam-aspirin combinations on the polyurethane sponge implantation model in the rat: *R. Garrett, B. Manthey, B. Vernon-Roberts & P. M. Brooks*
129S A comparison of isoxicam pharmacokinetics in young and elderly subjects: *C. F. George, A. G. Renwick, A. S. Darragh, J. Hosie, D. Blake, W. Van Marle & G. J. Frank*
135S Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers: *E. U. Kölle & K.-O. Vollmer*
143S Pharmacokinetics of isoxicam in hepatic disease: *N. Ferry, G. Cuisinaud, D. Ouzan, C. Trepo & J. Sassard*
149S Double-blind randomized controlled trial of isoxicam *vs* piroxicam in elderly patients with osteoarthritis of the hip and knee: *N. Bellamy, W. W. Buchanan & E. Grace*
157S Isoxicam *vs* ketoprofen in ankylosing spondylitis: *P. Doury & H. Roux*
161S Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents: *P. Massart & H. Bézes*
167S Double-blind multicentre UK hospital studies of isoxicam *vs* naproxen: *N. Cardoe & F. Dudley Hart*
173S Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis: *W. M. O'Brien*
183S Discussion 1
185S Discussion 2
187S Discussion 3
189S Closing remarks: *P. Brooks & A. M. Breckenridge*

Supplement 3 to Volume 22, 1986
Nicardipine: a new calcium antagonist

191S Introduction: *D. Julian*

Clinical pharmacology

193S Clinical pharmacology and its implications in everyday practice: *P. Turner*
195S A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride: *R. J. Dow & D. J. M. Graham*
203S A review of the haemodynamic effects of nicardipine in ischaemic heart disease: *B. Silke, M. A. Frais, S. P. Verma, G. Reynolds, S. H. Taylor & N. C. Jackson*
215S Effects of nicardipine on myocardial metabolism and coronary haemodynamics: a review: *C. Hanet, M. F. Rousseau, M.-F. Vincent & H. Pouleur*
231S Metabolic and endocrine consequences of calcium channel blockade: *J. Feely, M. Cullen & W. Collins*

The treatment of hypertension

237S The treatment of hypertension: *J. I. S. Robertson*
239S The acute and chronic effects of nicardipine on blood pressure, heart rate, neurocirculatory reflexes and renal function in hypertensive patients: *W. A. Littler, M. A. Young & S. A. Smith*
243S A trial comparing nicardipine and cyclopenthiazide K in a group of general practice patients with mild to moderate hypertension: *T. S. Murray, J. J. Langan & P. F. Coxhead*
249S Long-term effects of nicardipine in the treatment of essential hypertension: *T. S. Murray, J. J. Langan, P. F. Coxhead & N. Levinson*
259S Nicardipine *vs* propranolol in the treatment of essential hypertension: effect on total body elemental composition: *T. S. Murray, B. W. East & J. I. S. Robertson*
267S Psychological effects of nicardipine and propranolol on hypertensive patients: *J. S. Callender*
273S Nicardipine and verapamil in essential hypertension: *I. M. Al-Khawaja, M. P. Caruana, A. Lahiri, J. R. Whittington, J. G. Lewis & E. B. Raftery*
283S Nicardipine combined with enalapril in patients with essential hypertension: *R. Donnelly, H. L. Elliott & J. L. Reid*

289S Safety, efficacy and pharmacokinetics of nicardipine in elderly hypertensive patients: *S. T. Brown III, D. Freedman, G. de Vault, L. Slay & the Elderly Multicentre Study Group*
297S The effects of nicardipine in hypertensive subjects with impaired renal function: *S. M. Lee, R. Williams, D. Warnock, M. Emmett & R. A. Wolbach*

Calcium antagonists in the treatment of angina
307S The role of nicardipine in the treatment of angina pectoris—chairman's comments: *P. A. Poole-Wilson*
309S Lack of negative inotropic effect on heart muscle following infusion of nicardipine into patients with coronary artery disease. Effects of arterial pacing: *P. A. Poole-Wilson & D. P. Lipkin*
313S Effects of intracoronary nicardipine and nifedipine on left ventricular function and coronary sinus blood flow: *C. A. Visser, J. J. Koolen, H. B. van Wezel, R. Jonges, G. Hoedemaker & A. J. Dunning*
319S Calcium antagonists treatment and its effects on left ventricular function in patients with ischaemic heart disease: *E. A. Rodrigues, I. M. Al-Khawaja, A. Lahiri & E. B. Raftery*
325S Comparison of the efficacy of nicardipine and nifedipine in patients with chronic stable angina: *C. Armstrong, J. Garnham & R. Blackwood*
331S Long-term safety and efficacy of nicardipine in the treatment of stable angina pectoris: *C. Armstrong, J. Garnham, R. Blackwood, M. Laher & T. Counihan*
339S Nicardipine and propranolol in angina pectoris: a comparative study with special reference to ergometer working capacity tests: *P. Bjerle, B. O. Olofsson & O. Glimvik*
345S Comparative efficacy of nicardipine hydrochloride and atenolol in the treatment of chronic stable angina: *R. L. Logan, H. Ikram, M. W. Webster & W. Guppy*
351S Closing remarks: *D. Julian*